TScan Therapeutics
TCRX
28 hedge funds and large institutions have $14.8M invested in TScan Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
8% more funds holding
Funds holding: 26 → 28 (+2)
0.03% more ownership
Funds ownership: 50.23% → 50.26% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
49% less capital invested
Capital invested by funds: $29M → $14.8M (-$14.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NW
NewEdge Wealth
Pittsburgh,
Pennsylvania
|
+$224K |
| 2 |
NM
Newtyn Management
New York
|
+$73.6K |
| 3 |
Millennium Management
New York
|
+$47.2K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$27.6K |
| 5 |
Renaissance Technologies
New York
|
+$24.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$203K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$106K |
| 3 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$88K |
| 4 |
Morgan Stanley
New York
|
-$54.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.99K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACA
26
Atlas Capital Advisors
Jackson,
Wyoming
| $1.39K | – | – | – |
|
27
Bank of America
Charlotte,
North Carolina
| $362 | +$574 | +234 | New |
|
28
Wells Fargo
San Francisco,
California
| $113 | +$2 | +1 | +1% |
|
|
WP
29
Woodline Partners
San Francisco,
California
| – | -$203K | -66,601 | Closed |
|
|
MAM
30
Marquette Asset Management
Minneapolis,
Minnesota
| – | -$88K | -28,895 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -184 | Closed |
|
TCRX Hedge Fund Activity: Q4 2022 in Review
28 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2022, worth a combined $14.8M — down 49% from $29M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TCRX positions and 3 closed out — a net gain of 2 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was NewEdge Wealth, opening a new position worth an estimated $224K. The largest seller was Woodline Partners, exiting entirely with an estimated $203K sold.
- 28 institutional investors held TScan Therapeutics (TCRX) as of Q4 2022, up from 26 in Q3 2022.
- Funds reported $14.8M of TScan Therapeutics stock for Q4 2022, down 49% quarter-over-quarter.
- 5 funds opened new TScan Therapeutics positions in Q4 2022 and 3 closed out, a net change of +2 holders.
- The largest TScan Therapeutics buyer in Q4 2022 was NewEdge Wealth, an estimated $224K added.
- The largest TScan Therapeutics seller in Q4 2022 was Woodline Partners, an estimated $203K sold.
Based on aggregated 13F filings for Q4 2022.